Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2586184 in mild to moderate SLE
NCT01777256Phase 2Terminated
- Sponsor
- GSK
- Start
- Mar 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of solcitinib in systemic lupus erythematosus (SLE) (5 arms), sponsored by GSK. Primary endpoints: Percentage Inhibition from Baseline of interferon (IFN) Transcriptional Biomarkers at 2 weeks, Change from Baseline of SELENA SLEDAI score at 16 weeks and 3 more. Started Mar 2013; status: terminated.
02
Drugs
solcitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01777256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777256.